ROIVANT SCIENCES LTD. Interest Income, Other
ROIVANT SCIENCES LTD. (ROIV) reported Interest Income, Other of $10.25 million for the 3-month period ending 2022-12-31, per its 10-Q filed 2023-02-13.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2023-02-13
- ROIVANT SCIENCES LTD. interest income, other for the quarter ending 2022-12-31 was $10.25M, a 15428.79% increase year-over-year.
- ROIVANT SCIENCES LTD. interest income, other for the quarter ending 2022-09-30 was $5.67M, a 9045.16% increase year-over-year.
- ROIVANT SCIENCES LTD. interest income, other for the quarter ending 2022-06-30 was $1.98M, a 2690.14% increase year-over-year.
- ROIVANT SCIENCES LTD. interest income, other for the quarter ending 2022-03-31 was $170.00K, a 188.14% increase year-over-year.
- ROIVANT SCIENCES LTD. interest income, other for fiscal 2022 was $369.00K, a 73.98% decline from fiscal 2021.
- ROIVANT SCIENCES LTD. interest income, other for fiscal 2021 was $1.42M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2022-12-31 | $10.25M 10-Q · filed 2023-02-13 | $15.92M derived: sum of 2 quarters · filed 2023-02-13 | $17.90M 10-Q · filed 2023-02-13 | $18.07M derived: sum of 4 quarters · filed 2023-02-13 |
| 2022-09-30 | $5.67M 10-Q · filed 2022-11-14 | $7.65M 10-Q · filed 2022-11-14 | $7.82M derived: sum of 3 quarters · filed 2022-11-14 | $7.89M derived: sum of 4 quarters · filed 2023-02-13 |
| 2022-06-30 | $1.98M 10-Q · filed 2022-08-15 | $2.15M derived: sum of 2 quarters · filed 2022-08-15 | $2.22M derived: sum of 3 quarters · filed 2023-02-13 | $2.28M derived: sum of 4 quarters · filed 2023-02-13 |
| 2022-03-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $236.00K derived: sum of 2 quarters · filed 2023-02-13 | $298.00K derived: sum of 3 quarters · filed 2023-02-13 | $369.00K 10-K · filed 2022-06-28 |
| 2021-12-31 | $66.00K 10-Q · filed 2023-02-13 | $128.00K derived: sum of 2 quarters · filed 2023-02-13 | $199.00K 10-Q · filed 2023-02-13 | $258.00K derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $62.00K 10-Q · filed 2022-11-14 | $133.00K 10-Q · filed 2022-11-14 | $192.00K derived: sum of 3 quarters · filed 2022-11-14 | $351.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $71.00K 10-Q · filed 2022-08-15 | $130.00K derived: sum of 2 quarters · filed 2022-08-15 | $289.00K derived: sum of 3 quarters · filed 2022-08-15 | $868.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $218.00K derived: sum of 2 quarters · filed 2022-06-28 | $797.00K derived: sum of 3 quarters · filed 2022-06-28 | $1.42M 10-K · filed 2022-06-28 |
| 2020-12-31 | $159.00K 10-Q · filed 2022-02-14 | $738.00K derived: sum of 2 quarters · filed 2022-02-14 | $1.36M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $579.00K 10-Q · filed 2021-11-15 | $1.20M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $621.00K 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |